Decoding Your Diagnosis: Testing, Pathology, and Genetics
At a Glance
Adrenal cancer is evaluated first with hormone testing to safely rule out pheochromocytoma, then with CT imaging and, after surgery, pathology such as the Weiss score and Ki-67; genetic testing may identify inherited risk.
The journey to a diagnosis for an adrenal mass involves a careful sequence of imaging, hormone testing, and often genetic evaluation. Because some adrenal tumors produce powerful hormones that can cause a medical crisis if disturbed, the order of these tests is critical for your safety.
The First Rule: No Biopsy Before Hormone Testing
If you have an adrenal mass, your doctors must first determine if it is a Pheochromocytoma (PPGL)—a tumor that produces adrenaline-like hormones [1].
- The Risk: Performing a biopsy or surgery on an unrecognized PPGL can trigger a life-threatening “hypertensive crisis” (a sudden, extreme spike in blood pressure) [2].
- The Test: Doctors measure metanephrines in your blood or urine [1]. For the most accurate blood test, you should be lying flat on your back (supine) for at least 20 minutes before the blood is drawn [3].
- Other Hormone Checks: You will also likely have a dexamethasone suppression test to see if the tumor is making too much cortisol [4]. Depending on your symptoms, your doctor may also check aldosterone, renin, or male/female sex hormones [2].
Note: A biopsy is generally not a routine part of diagnosing a resectable adrenal tumor. Even after PPGL is ruled out, biopsies are mostly reserved for situations where doctors suspect the tumor might be a metastasis from another cancer or lymphoma.
Reading Your Imaging: The CT Scan
Imaging, specifically a Computed Tomography (CT) scan, provides clues about whether a tumor is benign (harmless) or malignant (cancerous). Radiologists use Hounsfield Units (HU) to measure the density of the tumor [5].
- < 10 HU: Tumors with low density (lots of intracellular lipid/fat) on an unenhanced CT are strongly suggestive of a benign adenoma [5].
- 10 to 20 HU: This is an indeterminate range.
- > 20 HU: Tumors with higher density are more concerning for Adrenocortical Carcinoma (ACC), PPGL, or a metastasis, but are not definitively cancer [6].
- Other Red Flags: Doctors also look for tumors larger than 4 cm, irregular shapes, contrast “washout” rates, or evidence that the tumor is invading nearby organs or blood vessels [7][5]. Size alone does not diagnose cancer.
Understanding the Pathology Report
If the tumor is removed, a pathologist examines the tissue under a microscope. Their report will include several key “scores” that help predict how the cancer might behave.
The Weiss Score
The Weiss score is a standard tool used to evaluate conventional adrenocortical tumors [8]. It looks at nine different features, such as how the cells look and whether the tumor is invading blood vessels.
- Score of 0–2: Suggests the tumor is likely benign (an adenoma), though borderline cases require expert review [8].
- Score of 3 or higher: Generally indicates Adrenocortical Carcinoma (ACC) [8].
- Note: Some rare variants, like oncocytic tumors, use different scoring systems (such as the Lin-Weiss-Bisceglia system) because they look different under the microscope [9][10].
The Ki-67 Index
The Ki-67 index measures how fast the cancer cells are dividing [11]. It is expressed as a percentage. A higher percentage means the tumor is more “aggressive” and may be more likely to return after surgery [11][12]. This number is a prognostic marker that your multidisciplinary team integrates with your stage, margins, and overall health to determine your follow-up plan [13].
The Role of Genetics
Hereditary risk is a major factor in adrenal tumors, though it varies significantly by the type of tumor.
- PPGL: Up to 35% or more of people with PPGL have an underlying germline genetic mutation (such as SDHx, VHL, or RET). Current medical guidelines recommend universal germline testing for almost everyone diagnosed with PPGL [14][15][16].
- ACC: Hereditary links in adult ACC are less common but do exist, such as Li-Fraumeni Syndrome (TP53 gene) or Lynch Syndrome [14][17]. Recommendations for testing depend heavily on your age (more common in childhood ACC), family history, and specific tumor features.
Finding a genetic link can help your doctors tailor your treatment and alert your family members through cascade testing. Genetic counseling is highly recommended before testing to help you understand the limits of a negative test, the possibility of uncertain results, and what the results mean for you and your family’s screening needs [18][19].
Common questions in this guide
Why do doctors check hormones before biopsying an adrenal mass?
What do Hounsfield unit numbers mean on an adrenal CT?
What does a Weiss score show in an adrenal tumor pathology report?
What does the Ki-67 index mean in an adrenal cancer pathology report?
Should someone with an adrenal tumor have genetic testing?
How should I prepare for a blood test for metanephrines?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Has my 'biochemical workup'—including tests for metanephrines—been completed and reviewed before we consider a biopsy or surgery?
- 2.What was the Hounsfield Unit (HU) measurement of my tumor on the unenhanced CT scan, and what does that tell us about its potential for malignancy?
- 3.What was the Ki-67 index in my pathology report, and how does that value influence my treatment plan?
- 4.If my Weiss score was between 2 and 4, how are you integrating that with my imaging and hormone levels to reach a final diagnosis?
- 5.Since you're recommending genetic testing, can you refer me to a genetic counselor to discuss the implications for me and my family?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (19)
- 1
Retroperitoneal paraganglioma mimicking a solid pseudopapillary neoplasm of the pancreatic tail and confirmed by percutaneous biopsy: a case report.
Song J, Sun W, Ren Y, et al.
Frontiers in oncology 2026; (16()):1838923 doi:10.3389/fonc.2026.1838923.
PMID: 42614150 - 2
European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M, Tsagarakis S, Terzolo M, et al.
European journal of endocrinology 2023; (189(1)):G1-G42 doi:10.1093/ejendo/lvad066.
PMID: 37318239 - 3
Biochemical Assessment of Pheochromocytoma and Paraganglioma.
Eisenhofer G, Pamporaki C, Lenders JWM
Endocrine reviews 2023; (44(5)):862-909 doi:10.1210/endrev/bnad011.
PMID: 36996131 - 4
Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M, Arlt W, Bancos I, et al.
European journal of endocrinology 2016; (175(2)):G1-G34 doi:10.1530/EJE-16-0467.
PMID: 27390021 - 5
Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study.
Bancos I, Taylor AE, Chortis V, et al.
The lancet. Diabetes & endocrinology 2020; (8(9)):773-781 doi:10.1016/S2213-8587(20)30218-7.
PMID: 32711725 - 6
Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry.
Petersenn S, Richter PA, Broemel T, et al.
European journal of endocrinology 2015; (172(4)):415-22 doi:10.1530/EJE-14-0916.
PMID: 25599706 - 7
Non-functioning adrenocortical carcinoma.
Lenh BV, Duc NM, Tra My TT, et al.
Radiology case reports 2021; (16(6)):1329-1334 doi:10.1016/j.radcr.2021.03.006.
PMID: 33889224 - 8
Diagnosis and grading of adrenal cortical carcinoma.
Vocino Trucco G, Duregon E, Papotti M, Volante M
Virchows Archiv : an international journal of pathology 2026; (488(1)):193-210 doi:10.1007/s00428-025-04278-0.
PMID: 41057662 - 9
Overview of the 2022 WHO Classification of Adrenal Cortical Tumors.
Mete O, Erickson LA, Juhlin CC, et al.
Endocrine pathology 2022; (33(1)):155-196 doi:10.1007/s12022-022-09710-8.
PMID: 35288842 - 10
Challenges in surgical pathology of adrenocortical tumours.
Erickson LA
Histopathology 2018; (72(1)):82-96 doi:10.1111/his.13255.
PMID: 29239032 - 11
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
Fassnacht M, Dekkers OM, Else T, et al.
European journal of endocrinology 2018; (179(4)):G1-G46 doi:10.1530/EJE-18-0608.
PMID: 30299884 - 12
Comparison of the methods for measuring the Ki-67 labeling index in adrenocortical carcinoma: manual versus digital image analysis.
Yamazaki Y, Nakamura Y, Shibahara Y, et al.
Human pathology 2016; (53()):41-50.
PMID: 26980031 - 13
Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases.
Duregon E, Volante M, Bollito E, et al.
Human pathology 2015; (46(12)):1799-807.
PMID: 26472162 - 14
Precision Care for Hereditary Urologic Cancers: Genetic Testing, Counseling, Surveillance, and Therapeutic Implications.
Somoto T, Utsumi T, Ikeda R, et al.
Current oncology (Toronto, Ont.) 2025; (32(12)) doi:10.3390/curroncol32120698.
PMID: 41440226 - 15
[Adrenal tumors: current standards in clinical management].
Fuß CT, Megerle F, Fassnacht M
Innere Medizin (Heidelberg, Germany) 2024; (65(7)):632-641 doi:10.1007/s00108-024-01727-x.
PMID: 38864873 - 16
Current prospects of hereditary adrenal tumors: towards better clinical management.
Ohmoto A, Hayashi N, Takahashi S, Ueki A
Hereditary cancer in clinical practice 2024; (22(1)):4 doi:10.1186/s13053-024-00276-6.
PMID: 38532453 - 17
Adrenocortical carcinoma (ACC): When and why should we consider germline testing?
Petr EJ, Else T
Presse medicale (Paris, France : 1983) 2018; (47(7-8 Pt 2)):e119-e125 doi:10.1016/j.lpm.2018.07.004.
PMID: 30104051 - 18
Li-Fraumeni Syndrome With Six Primary Tumors-Case Report.
Stojiljković D, Cvetković A, Jokić A, et al.
Case reports in oncological medicine 2024; (2024()):6699698 doi:10.1155/2024/6699698.
PMID: 38765733 - 19
Genetic Testing for Adrenal Tumors-What the Contemporary Surgeon Should Know.
Bates MF, Sorensen MJ
Surgical oncology clinics of North America 2023; (32(2)):303-313 doi:10.1016/j.soc.2022.10.007.
PMID: 36925187
This page explains adrenal cancer testing, pathology, and genetic risk for informational purposes only and does not constitute medical advice. Ask your care team to interpret your specific results and recommend next steps.
Get notified when new evidence is published on Adrenal gland cancer.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.